Humanized anti-Lewis Y antibodies : In vitro properties and pharmacokinetics in rhesus monkeys

• Published in: Cancer research (Chicago, Ill.) Ill.), 1996-03, Vol.56 (5), p.1118-1125
• Main Authors: MAN SUNG CO, BAKER, J, LOIBNER, H, BEDNARIK, K, JANZEK, E, NERUDA, W, MAYER, P, PLOT, R, STUMPER, B, VASQUEZ, M, QUEEN, C
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; Antibodies, Monoclonal - genetics; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacokinetics; Antineoplastic agents; Base Sequence; Biological and medical sciences; Cells, Cultured; DNA, Complementary - genetics; Humans; Immunotherapy; Lewis Blood-Group System - immunology; Lymphocyte Activation; Macaca mulatta; Medical sciences; Mice; Molecular Sequence Data; Pharmacology. Drug treatments; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; Recombinant Fusion Proteins - pharmacokinetics
• ISSN: 0008-5472; 1538-7445

ABL 364 is a murine monoclonal IgG3 antibody directed against the Lewis Y carbohydrate antigen (Le(y)) expressed on the surface of many epithelial cell tumors. The antibody mediates cytotoxicity via activation of human complement or human effector cells, and has been evaluated in several clinical trials including two Phase I/II trials in relapsed small cell lung cancer and metastatic breast cancer. To improve the effector functions of the antibody, increase its half-life in circulation, and avoid the human antimouse antibody response, two chimeric and several humanized antibodies were constructed for evaluation. The chimeric IgG1 is more potent than the murine IgG3 in tumor cell lysis via activation of human peripheral mononuclear cells (10-fold), but somewhat less effective in complement-dependent lysis (2-3 fold). The chimeric IgG3 is slightly less potent than the IgG1. A humanized IgG1 was constructed by combining the complementarity-determining regions of the ABL 364 antibody with human framework and constant regions. Several additional variants were subsequently constructed to improve the binding affinity and increase expression of the antibody. Two of the variants, designated I and K, differ by a single amino acid at position 75 of the heavy chain. Both variants have affinity within 2-fold of the chimeric IgG1 antibody and retain the cytolytic activities toward tumor cell lines. However, it was possible to express variant K at a significantly higher level (5- 10-fold) than variant I. Pharmacokinetics of the humanized ABL 364 antibody variant K was compared with that of the parent murine antibody in rhesus monkeys. It was shown that the terminal half-life of the humanized antibody in rhesus monkeys is 14-20 days, with a mean of 16.3 days, while that of the parent murine antibody is only 1.9 days.